Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T

BMC Pharmacology

Volumn 5, Issue , 2005, Pages

  Hassan, Madiha A H ^a   Ketat, Amal F ^b  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CYCLIC GMP; ISOPRENALINE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TROPONIN T; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GUANOSINE PHOSPHATE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL SECRETION; CELLULAR PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; ENERGY CONSUMPTION; ENZYME ACTIVITY; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; SURVIVAL RATE; ANIMAL; BLOOD; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; DIET THERAPY; ENZYMOLOGY; METABOLISM; STATISTICAL MODEL;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMYOPATHIES; CREATINE KINASE; GUANOSINE MONOPHOSPHATE; ISOPROTERENOL; LINEAR MODELS; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; SULFONES; TROPONIN T;

EID: 26844453717     PISSN: 14712210     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-5-10     Document Type: Article

References (31)

1. Andersson KE: Pharmacology of penile erection. Pharmacol Rev 2001, 53:417-450.
2. ATP channels in rabbits. Am J Physiol 2002, 283:H1263-H1269.
3. Salloum F, Yin C, Xi L, Kukreja RC: Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003, 92(6):595-597.
4. Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ: Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate- specific phosphodiesterase 5. Drugs Exp Clin Res 2002, 28(6):213-219.
5. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiological Rev 1999, 79:216-248.
6. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS: Nitric oxide, atrial natriuretic peptide and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998, 10:812-818.
7. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M: Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003, 111(9):1399-1407.
8. Mudersu F, Elsner D: Animal models of chronic heart failure:. Pharmacol Res 2000, 41(6):605-612.
9. Teerlink JR, Pfeffer JM, Pfeffer MA: Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994, 75:105-113.
10. Shi YR, Bu DF, Qi YF, Gao L, Jiang HF, Pang YZ, Tang CS, Du JB: Dysfunction of myocardial taurine transport and effect of taurine supplement in rats with Isoproterenol-induced myocardial injury. Acta Pharmacol Sin 2002, 23(10):910-918.
11. Verhagen AMG, Attia DMA, Koomans HA, Joles JA: Male gender increases sensitivity to proteinuria induced by mild NOS inhibition in rats: role of sex hormones. Am J Physiol Renal Physiol 2000, 279:F664-F670.
12. Porstmann T, Kiessing ST: Enzyme immunoassay techniques. An overview. J Immunol Methods 1992, 150:5-21.
13. Horder M, Elser RC, Gerhardt W, Mathieu M, Sampson EJ: Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes: part 7: IFCC method for creatine kinase. Eur J Clin Chem Clin Biochem 1991, 29(7):435-456.
14. Lowry OH, Rosenbrough NT, Farr AL, Randall RJ: Protein measurements with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
15. Field A: Discovering statistics: using SPSS for Windows. Sage Publications London; 2000.
16. Lorell BH, Carabello BA: Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000, 102:470-479.
17. Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Helmy M, Siragy HM: Angiotensin receptor blockers: Evidence for preserving target organs. Clin Cardiol 2001, 24:183-190.
18. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM: Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem J 1992, 281:21-40.
19. O'Brien PJ, Dameron GW, Beck ML, Kang YJ, Erickson BK, Di Battista TH, Miller KE, Jackson KN, Mittelstadt S: Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci 1997, 47:486-495.
20. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F: Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003, 93(10):907-916.
21. Conti M, Jin SL: The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999, 63:1-17.
22. Traverse JH, Chen YJ, Du R, Bache RJ: Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000, 102:2997-3002.
23. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass KA: Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001, 15:1718-1726.
24. Mohan P, Brutsaert DL, Paulus WJ, Sys SU: Myocardial contractile response to nitric oxide and cGMP. Circulation 1996, 93:1223-1229.
25. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ: Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999, 84:1020-1031.
26. Balligand JL: Regulation of cardiac beta-adrenergic response by nitric oxide. Cardiovasc Res 1999, 43:607-620.
27. Hare JM, Givertz MM, Creager MA, Colucci WS: Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998, 97:161-166.
28. Straznicka M, Gong G, Yan L, Scholz PM, Weiss HR: Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes. J Cardiovasc Pharmacol 1999, 34:229-236.
29. Calderone A, Thaik CM, Takahashi N, Chang DF, Colucci WS: Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998, 101:812-818.
30. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF: Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. JBC 2003, 278:47694-47699.
31. Kishimoto I, Rossi K, Garbers DL: A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. PNAS 2001, 98:2703-2706.